Recall that Cytori lost a patent battle to the University of Pittsburgh associated with this group:
POWAY, CALIFORNIA (PRWEB) SEPTEMBER 12, 2017
VetStem Biopharma, Inc., announced that a major new European patent has been granted to the University of Pittsburgh and VetStem has full license to that patent. This patent covers methods for isolating stem cells from adipose tissue, the composition of the adipose-derived stem cell itself, combining this stem cell with matrix materials, and incorporating the stem cells in an implant. This patent will provide coverage for the on-going commercial and development programs at VetStem and may be available for licensing to other companies interested in working in this field.
This new patent adds to the other patents in the VetStem portfolio that cover methods of using regenerative cells from adipose tissue for the eye, pancreas, liver, bone and muscle. VetStem has exclusive worldwide rights for veterinary use of these other licensed patents and this strengthens further the company’s intellectual property position in this rapidly developing field.
As the first company in the United States to offer fat derived stem cell services for veterinary use, VetStem has rapidly developed the market, providing treatments to over 13,000 horses, dogs, cats and exotic species. “Intellectual property rights are critical and can be confusing in a rapidly developing market with evolving technology.” said Bob Harman, DVM, MPVM, CEO of VetStem. “We have taken appropriate actions to protect the market that we are creating in regenerative veterinary medicine and to ensure that the value of the company is optimized. The value of this technology has increased greatly since the founding of the company in 2002 as the business model has evolved and many companies and Universities worldwide have validated the therapeutic activity of these cells.”
About VetStem Biopharma, Inc.
VetStem Biopharma is a veterinarian-lead Company that was formed in 2002 to bring regenerative medicine to the profession. This privately held biopharmaceutical enterprise, based near San Diego (California), currently offers veterinarians an autologous stem cell processing service (from patients’ own fat tissue) among other regenerative modalities. With a unique expertise acquired over the past 15 years and 13,000 patients treated by veterinarians for joint, tendon or ligament issues, VetStem has made regenerative medicine applications a therapeutic reality beyond the realm of research. The VetStem team is focused on developing new clinically practical and affordable veterinary solutions that leverage the natural restorative abilities present in all living creatures. The Company’s stated mission being “to extend and enhance the lives of animals by improving the quality of recovery in acute conditions, but also by unlocking ways to slow, stop and ultimately revert the course of chronic diseases”. In addition to its’ own portfolio of patents, VetStem holds exclusive global veterinary licenses to a portfolio of over 70 issued patents in the field of regenerative medicine.